Home > Kliniken und Institute > Nephrologie > Forschung > AG Prof. Böger > Publications
AG Prof. Böger


< zurück zu AG Prof. Böger

  1. Pattaro C*, Köttgen A*, Teumer A*, Garnaas M*, Böger CA*, et al. Genome-wide association and functional follow-up reveals new loci for kidney function. PLoS Genet 2012;8(3):e1002584. * shared first authorship. IF 8.517 (2012)
  2. Böger CA , Gorski M, Hoffmann MM, et al. Association of eGFR-related loci identified by GWAS with incident CKD and ESRD. PLoS Genet 2011;7(9):e1002292. IF 8.694 (2011)
  3. Böger CA *, Chen MH*, Tin A*, Olden M*, Köttgen A*, de Boer IH*, et al. CUBN is a gene locus for albuminuria. J Am Soc Nephrol 2011;22:555-70. * shared first authorship. IF 9.663 (2011)
  4. Köttgen A*, Pattaro C*, Böger CA*, Fuchsberger C*, et al. New loci associated with kidney function and chronic kidney disease. Nat Genet 2010;42:376-84. * shared first authorship. IF 36.377 (2010)
  5. Götz AK*, Böger CA*, Popal M, Banas B, Krämer BK. Effect of membrane flux and dialyzer biocompatibility on survival in end-stage diabetic nephropathy. Nephron Clin Pract 2008;109:c154-60. * shared first authorship. IF 1.715 (2008)
  6. Böger CA, Stubanus M, Haak T, Götz AK, Christ J, Hoffmann U, Riegger GAJ, Krämer BK. Effect of MTHFR C677T genotype on survival in type 2 diabetes patients with end stage diabetic nephropathy. Nephrol Dial Transplant 2006;22:154-62. IF 3.154 (2006)
  7. Böger CA , Haak T, Götz AK, Christ J, Ruff E, Hoffmann U, Riegger GAJ, Krämer BK. Effect of ACE and AT-2 inhibitors on mortality and progression to microalbuminuria in a nested case control study of diabetic nephropathy in diabetes mellitus type 2: results from the GENDIAN study. Int J Clin Pharmacol Ther 2006;44:364-74. IF 1.361 (2006)
  8. Böger CA , Götz A, Krüger B, Hösl M, Schmitz G, Riegger GAJ, Krämer BK. Effect of genetic variation on therapy with angiotensin converting enzyme inhibitors or angiotensin receptor blockers in dialysis patients. Eur J Med Res 2005;10:161-8. IF 1.25 (2005)
  9. Böger CA , Fischereder M, Deinzer M, Aslanidis C, Schmitz G, Stubanus M, Banas B, Krüger B, Riegger GAJ, Krämer BK. RANTES gene polymorphisms predict risk for all-cause and cardiac mortality in type 2 diabetes mellitus hemodialysis patients. Atherosclerosis 2005;183:121-9. IF 3.777 (2005)
  10. Böger CA , Götz A, Stubanus M, Banas B, Deinzer M, Krüger B, Holmer SR, Schmitz G, Riegger GAJ, Krämer BK. C-reactive protein as predictor of death in end stage diabetic nephropathy: role of peripheral arterial disease. Kidney Int 2005;68:217-27. IF 4.927 (2005)
  11. Götz AK*, Böger CA*, Hirschmann C, Schmitz G, Riegger GAJ, Krämer BK. Effect of HMG-CoA-reductase inhibitors on survival in type 2 diabetes patients with end stage diabetic nephropathy. Eur J Med Res 2005;10:155-60. * shared first authorship IF 1.25 (2005)
  12. Burghardt T, Kastner J, Suleiman H, Rivera-Milla E, Stepanova N, Lottaz C, Kubitza M, Böger CA, Schmidt S, Gorski M, de Vries U, Schmidt H, Hertting I, Kopp J, Rascle A, Moser M, Heid IM, Warth R, Spang R, Wegener J, Mierke CT, Englert C, Witzgall R. LMX1B is essential for the maintenance of differentiated podocytes in adult kidneys. J Am Soc Nephrol 2013;24:1830-48. IF 8.98 (2012)
  13. Chasman DI, Fuchsberger C, Pattaro C, Teumer A, Böger CA, et al. Integration of genome-wide association studies with biological knowledge identifies six novel genes related to kidney function. Hum Mol Genet. 2012 Sep 25. IF 7.636 (2011)
  14. Okada Y, …, Böger CA*, et al. Meta-analysis identifies multiple loci associated with kidney function-related traits in east Asian populations. Nat Genet 2012;44(8):904-9. *author named in Supplement       . IF 35.532 (2011)
  15. Reznichenko A, Böger CA, Snieder H, et al. UMOD as a susceptibility gene for end stage renal disease. BMC Med Genet 2012;13(1):78. IF 2.33 (2011)
  16. Ellis JW, Chen MH, Foster MC, Liu CT, Larson MG, deBoer I, Köttgen A, Parsa A, Bochud M, Böger CA, Kao L, Fox CS, O’Seaghdha CM. Validated SNPs for eGFR and their associations with albuminuria. Hum Mol Genet 2012;21(14):3293-8. IF7.636 (2011)
  17. ICBP, Ehret GB, …, Böger CA*, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 2011;478(7367):103-9. *author named in Supplement. IF 36.280 (2011)
  18. Jungbauer CG, Birner C, Jung B, … Böger CA, et al. Kidney injury molecule-1 and N-acetyl-beta-D-glucosaminidase in chronic heart failure: possible biomarkers of cardiorenal syndrome. Eur J Heart Fail 2011;13(10):1104-10. IF 4.896 (2011)
  19. Gronwald W, Klein MS, Zeltner R, Schulze BD, Reinhold SW, Deutschmann M, Immervoll AK, Böger CA, Banas B, Eckardt KU, Oefner PJ. Detection of autosomal dominant polycystic kidney disease by NMR spectroscopic fingerprinting in urine. Kidney Int; 2011;79:1244-53. IF 6.606 (2011)
  20. Krüger B, Banas MC, Walberer A, Böger CA, Farkas S, Hoffmann U, Fischereder M, Banas B, Krämer BK. A comprehensive genotype-phenotype interaction of different   Toll-like receptor variations in a renal transplant cohort. Clin Sci (Lond) 2010;119:535-44. IF 4.613 (2010)
  21. Krüger B, Walberer A, Debler J, Böger CA, Farkas S, Reinhold SW, Obed A, Schlitt HJ, Fischereder M, Banas B, Krämer BK. Is inflammation prior to renal transplantation predictive for cardiovascular outcomes? Atherosclerosis 2010;210:637-42. IF 4.086 (2010)
  22. Baumeister SE, Böger CA, Krämer BK, Döring A, Eheberg D, Fischer B, John J, Koenig W, Meisinger C. Effect of chronic kidney disease and comorbid conditions on health care costs: a 10-year observational study in a general population. Am J Nephrol 2010;31:222-9. IF 2.658 (2010)
  23. Reinhold SW, Uihlein DC, Böger CA, Kloiber S, Frölich K, Bergler T, Banas B, Schweda F, Krämer BK. Renin, Endothelial NO synthase, and endothelin gene expression in the 2 kidney 1-clip Goldblatt Model of long-term renovascular hypertension. Eur J Med Res 2009;14:520-5. IF 1.04 (2009)
  24. Henning BF, Kuchlbauer S, Böger CA, Obed A, Farkas S, Zülke C, Scherer MN, Walberer A, Banas M, Krüger B, Schlitt HJ, Banas B, Krämer BK. Percutaneous transluminal angioplasty as first-line treatment of transplant renal artery stenosis. Clin Nephrol 2009;71:543-9. IF 1.373 (2009)
  25. Krüger B, Böger CA, Schröppel B, Farkas S, Schnitzbauer AA, Hoffmann U, Obed A, Murphy BT, Banas B, Krämer BK.   No effect of C-reactive protein (CRP) haplotypes on CRP levels and post-transplant morbidity and mortality in renal transplantation. Transpl Int 2008;21:452-8. IF 3.115 (2008)
  26. Banas MC, Banas B, Wolf J, Hoffmann U, Krüger B, Böger CA, Orth SR, Krämer BK. Smoking behaviour of patients before and after transplantation. Nephrol Dial Transplant 2008;23:1442-6. IF 3.568 (2008)
  27. Krüger B, Böger CA, Schröppel B, Obed A, Hoffmann U, Murphy BT, Fischereder M, Holler E, Banas B, Krämer BK. Impact of NOD2/CARD15 haplotypes on the outcome after kidney transplantation. Transpl Int. 2007;20:600-7. IF 2.146 (2006)
  28. Krüger B, Böger CA, Obed A, Farkas S, Hoffmann U, Banas B, Fischereder M, Krämer BK. RANTES/CCL5 polymorphisms as a risk factor for recurrent acute rejection. Clin Transplant. 2007;21:385-90 IF 2.051 (2006)
  29. Krüger B, Fischereder M, Jauch KW, Graeb C, Hoffmann U, Böger CA, Banas B, Obed A, Schlitt HJ, Krämer BK. Five-year follow-up after late conversion from calcineurin inhibitors to sirolimus in patients with chronic renal allograft dysfunction. Transplant Proc. 2007;39:518-21. IF 0.962 (2006)
  30. Fredersdorf S, Weil J, Ulucan C, Birner C, Büttner R, Schubert T, Böger CA, Debl K, Muders F, Riegger GA, Luchner A. Vasopeptidase inhibition attenuates proteinuria and podocyte injury in Zucker diabetic fatty rats. Naunyn Schmiedebergs Arch Pharmacol. 2007;375:95-103. IF 2.779 (2006)
  31. Hoffmann U, Banas B, Krüger B, Banas M, Bergler T, Böger C, Kammerl M, Obed A, Rümmele P, Segerer S, Riegger GAJ, Krämer BK.   SDF-1 expression is elevated in chronic human renal allograft rejection. Clin Transplant 2006;20:712-8. IF 2.051 (2006)
  32. Weingart C, Leingaertner T, Bergler T, Krüger B, Böger C, Mack M, Banas B, Krämer BK. Increase in renal vascular resistance after intake of cyclosporin A and tacrolimus and reversal by nitroglycerin spray: A study in patients with stable renal allograft function. Int J Clin Pharmacol Ther 2006;44:422-7. IF 1.361 (2006)
  33. Krüger B, Schnitzbauer AA, Böger CA, Hoffmann U, Banas B, Farkas S, Schlitt HJ, Obed A, Krämer BK. Pretransplant calcium levels have no predictive value for delayed graft function, long-term graft function, cardiovascular events, or graft and patient survival in renal transplantation. Transplant Proc. 2006;38:697-700. IF 0.962 (2006)
  34. Krämer BK, Böger C, Marienhagen J, Pietrzyk M, Obed A, Mack M, Banas B. Cardiovascular risk estimates and risk factors in renal transplant recipients. Transplant Proc 2005;37:1868-70. IF 0.799 (2005)
  35. Endemann DH, Wolf K, Boeger CA, Riegger GA, Krämer BK. Adrenal aldosterone biosynthesis is elevated in a model of chronic renal failure – role of local adrenal renin-angiotensin system. Nephron Physiol 2004;97(2):37-44. IF 2.528 (2009)
  36. Reininger CB, Boeger CA, Steckmeier B, Spannagl M, Schweiberer L. Mechanisms underlying increased platelet reactivity in patients with peripheral arterial disease. Preliminary results. Int Angiol 1999;18(2):163-70. IF 1.182 (1999)
  37. Reininger CB, Lasser R, Rumitz M, Böger C, Schweiberer L. Computational analysis of platelet adhesion and aggregation under stagnation point flow conditions. Comput Biol Med 1999;29:1-18. IF 0.518 (1999)
  38. Böger CA , Heid IM. Chronic Kidney Disease: Novel Insights from Genome-Wide Association Studies. Kidney Blood Press Res 2011; 34(4):225-34. IF 1.464 (2011)
  39. Böger CA , Banas B, Krämer BK. Differential diagnosis and therapy of pulmorenal syndrome—the nephrologist’s perspective. Dtsch Med Wochenschr. 2007 Sep;132:1842-7. IF 0.433 (2007)
  40. Krämer BK, Böger C, Pietrzyk M, Obed A, Schlitt HJ, Mack M, Banas B. Cardiovascular risk factors after renal transplantation. Mitt Klin Nephrologie 2005;34:167-73.
  41. Krämer BK, Böger CA, Götz A, Banas B. Stellenwert von niedrigdosiertem Dopamin in der Prophylaxe oder Therapie des akuten Nierenversagens. Intensivmed 2004;41:616-7.       
  42. Böger CA , H. Kellner. Neurologische Komplikationen der Therapie rheumatischer Erkrankungen. Akt Rheumatol 2001;26:285-90. IF 0.241 (2004)
  43. Böger CA. Do we need to check our genes for a correct estimate of GFR? Am J Kidney Dis 2014;63:4-6. IF xxx (2012).
  44. Böger CA . It’s not only the kidneys -- genetic determinants of glomerular filtration marker levels. Nephrol Dial Transplant 2013;28:2397-8. IF 3.396 (2011)
  45. Böger CA , Kronenberg F. How healthy are your vessels? – Check your urine! Atherosclerosis 2012;220(1):38-41. IF 3.794 (2011)
  46. Böger CA , Sedor JR. GWAS of diabetic nephropathy: is the GENIE out of the bottle? PLoS Genet 2012;8(9): e1002989. IF 8.694 (2011)
  47. Böger CA . Kapitel 6: Sonstige klinische Einsatzgebiete von Azathioprin. in: Azathioprin in der Gastroenterologie. Unimed Verlag AG; 2002, 1. Auflage, Seite 92-101.
  48. Böger CA , Mertens PR. Kapitel 3: Genetic risk factors for diabetic nephropathy. in: Diabetes and Kidney Disease, Wiley-Blackwell. 1. Auflage. Editor: G. Wolf.
  49. Böger CA , Rümmele P, Mihatsch MJ, Banas B, Krämer BK. Reverse intrarenal diastolic flow due to calcineurin inhibitor (CI) toxicity. Am J Transplant 2006;6:1963-7. IF 6.843 (2006)
  50. Boeger CA , Schattenkirchner M, Kellner H. Infliximab bei Morbus Still – eine Fallbeschreibung. Z Rheumatol 2001;60 (Suppl 1):I/27. IF 0.669 (2005)
  51. Boeger CA , Wittwer H, Schattenkirchner M, Kellner H, Kellner W. Treatment of ankylosing spondylitis with infliximab. Ann Rheum Dis 2001;60:1159-60. IF 6.956 (2005)
  52. Böger CA , Schroll S, Holmer S. Ximelagatran for secondary prevention of venous thromboembolism. N Engl J Med. 2004;350(6):618-9. author reply 618-9.
  53. Krüger B, Böger C, Stubanus M, Fischereder M, Krämer BK. The COOPERATE trial. Lancet 2003;361:1054; author reply 1055.
  54. Banas B, Böger C, Krämer B. Everolimus in cardiac-transplant recipients. N Engl J Med 2003;349:2271-2; author reply 2271-2.

Updated April 1, 2014

< zurück zu AG Prof. Böger

© Universitätsklinikum Regensburg | Impressum | Disclaimer
Letzte Aktualisierung: 31.03.2014 | Online-Redaktion
Über uns
Beruf und Karriere
Universität Regensburg